Recent clinical and preclinical studies have demonstrated that modulation of the Wnt/β-catenin signaling pathway using pharmacological agents such as lithium, SB216763, and sulindac, or by targeting the transcriptional factor with a PPARγ agonist, may offer therapeutic benefits for neurodevelopmental delays (Zhuang et al., 2023). This evidence concerns the gene PPARG and Neurodevelopmental delay.